{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:40:59Z","timestamp":1792683659127,"version":"4.5.0"},"reference-count":135,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cgh.2019.03.037","type":"journal-article","created":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T19:20:57Z","timestamp":1553714457000},"page":"1655-1668.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":317,"title":["Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases"],"prefix":"10.1016","volume":"17","author":[{"given":"Konstantinos","family":"Papamichael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil Y.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Kozuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Raffals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Baidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Bressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles P.","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando S.","family":"Velayos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2019.03.037_bib1","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.clinthera.2016.03.018","article-title":"Efficacy and safety profile of anti-tumor necrosis factor-\u03b1 versus anti-integrin agents for the treatment of Crohn's disease: a network meta-analysis of indirect comparisons","volume":"38","author":"Miligkos","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib2","article-title":"Biological therapies in inflammatory bowel disease: beyond anti-TNF therapies","author":"Katsanos","year":"2018","journal-title":"Clin Immunol"},{"key":"10.1016\/j.cgh.2019.03.037_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Loss of response to anti-TNF treatments in Crohn's disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib4","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1097\/MIB.0000000000001231","article-title":"Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window","volume":"23","author":"Papamichael","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/MIB.0000000000000202","article-title":"Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse","volume":"21","author":"Papamichael","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/flgastro-2016-100685","article-title":"Use of anti-TNF drug levels to optimise patient management","volume":"7","author":"Papamichael","year":"2016","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib7","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/imj.14064","article-title":"Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays","volume":"49","author":"Barclay","year":"2019","journal-title":"Intern Med J"},{"key":"10.1016\/j.cgh.2019.03.037_bib8","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/ajg.2014.146","article-title":"Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases","volume":"109","author":"Roblin","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cgh.2013.07.010","article-title":"Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases","volume":"12","author":"Roblin","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib10","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib11","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/MIB.0000000000001182","article-title":"Serum adalimumab levels predict successful remission and safe deintensification in inflammatory bowel disease patients in clinical practice","volume":"23","author":"Aguas Peris","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/MIB.0000000000000689","article-title":"Higher adalimumab levels are associated with histologic and endoscopic remission in patients with Crohn's disease and ulcerative colitis","volume":"22","author":"Yarur","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib13","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib14","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1097\/MIB.0000000000000138","article-title":"Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD","volume":"20","author":"Frederiksen","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib15","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.12869","article-title":"Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease","volume":"40","author":"Mazor","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s00535-013-0803-4","article-title":"Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn\u2019s disease","volume":"49","author":"Imaeda","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00535-013-0829-7","article-title":"Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment","volume":"49","author":"Imaeda","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ecco-jcc\/jjw014","article-title":"Higher adalimumab drug levels are associated with mucosal healing in patients with Crohn's disease","volume":"10","author":"Zittan","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jgh.13400","article-title":"Association between serum adalimumab concentrations and endoscopic disease activity in patients with Crohn's disease","volume":"31","author":"Morita","year":"2016","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3109\/00365521.2016.1144781","article-title":"Prediction of clinical and endoscopic responses to anti-tumor necrosis factor-\u03b1 antibodies in ulcerative colitis","volume":"51","author":"Morita","year":"2016","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib21","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/apt.14318","article-title":"Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial","volume":"46","author":"Nakase","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib22","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1007\/s10620-018-5202-5","article-title":"Maintenance adalimumab concentrations are associated with biochemical, endoscopic and histologic remission in inflammatory bowel disease","volume":"63","author":"Juncadella","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2019.03.037_bib23","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41395-018-0073-0","article-title":"Prospective observational evaluation of time-dependency of adalimumab immunogenicity and drug concentrations: the Poetic Study","volume":"113","author":"Ungar","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib24","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/MPG.0000000000002051","article-title":"Association between infliximab drug and antibody levels and therapy outcome in pediatric inflammatory bowel diseases","volume":"67","author":"Ungar","year":"2018","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2019.03.037_bib25","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjy111","article-title":"Higher infliximab trough levels are associated with better outcome in paediatric patients with inflammatory bowel disease","volume":"12","author":"Van Hoeve","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib26","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/apt.12968","article-title":"Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis","volume":"40","author":"Baert","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.cgh.2014.01.033","article-title":"Early trough levels and antibodies to infliximab predict safety and success of re-initiation of infliximab therapy","volume":"12","author":"Baert","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib28","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2019.03.037_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1136\/gutjnl-2014-307882","article-title":"Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial","volume":"65","author":"Baert","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ecco-jcc\/jjw122","article-title":"Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis","volume":"11","author":"Papamichael","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib31","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/apt.14943","article-title":"Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing","volume":"48","author":"Verstockt","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib32","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/gutjnl-2013-305259","article-title":"The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab","volume":"63","author":"Ungar","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib33","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cgh.2015.10.029","article-title":"Pharmacokinetic features and presence of anti-drug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis","volume":"14","author":"Brandse","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A\u00a0real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2014.07.027","article-title":"Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn\u2019s disease","volume":"13","author":"Drobne","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/ibd\/izy217","article-title":"Higher postinduction infliximab serum trough levels are associated with healing of fistulizing perianal Crohn's disease in children","volume":"25","author":"El-Matary","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib37","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1097\/MIB.0000000000001126","article-title":"Therapeutic drug monitoring to guide infliximab dose adjustment is associated with better endoscopic outcomes than clinical decision making alone in active inflammatory bowel disease","volume":"23","author":"Kelly","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib38","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cgh.2017.03.031","article-title":"Improved long-term outcomes of patients with inflammatory bowel disease receiving proactive compared with reactive monitoring of serum concentrations of infliximab","volume":"15","author":"Papamichael","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib39","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1097\/MIB.0000000000000156","article-title":"Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study","volume":"20","author":"Vaughn","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib40","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/MIB.0000000000001223","article-title":"Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study","volume":"23","author":"Roblin","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.crohns.2014.01.009","article-title":"Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment","volume":"8","author":"Marits","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib42","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cgh.2014.12.026","article-title":"Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy","volume":"13","author":"Yarur","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib43","first-page":"1359","article-title":"Knowledge of fecal calprotectin and infliximab trough levels alters clinical decision-making for IBD outpatients on maintenance infliximab therapy","volume":"21","author":"Huang","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"Steenholdt","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib45","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.14458","article-title":"Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis","volume":"47","author":"Papamichael","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib46","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/1756283X17722916","article-title":"Clinical performance of an infliximab rapid quantification assay","volume":"10","author":"Magro","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib47","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","article-title":"Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis","volume":"147","author":"Adedokun","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjw133","article-title":"Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2\/3 PURSUIT induction and maintenance studies","volume":"11","author":"Adedokun","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib49","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1053\/j.gastro.2018.01.043","article-title":"Pharmacokinetics and exposure response relationships of ustekinumab in patients with Crohn's disease","volume":"154","author":"Adedokun","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.gastro.2011.09.034","article-title":"Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped","volume":"142","author":"Louis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.cgh.2014.11.026","article-title":"Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission","volume":"13","author":"Papamichael","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib52","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/ecco-jcc\/jjy021","article-title":"Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn's disease patients treated with combined immunosuppressive therapy","volume":"12","author":"Kang","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib53","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/apt.13970","article-title":"Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease","volume":"45","author":"Yarur","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib54","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/MIB.0000000000001220","article-title":"The association between drug levels and endoscopic recurrence in postoperative patients with Crohn's disease treated with tumor necrosis factor inhibitors","volume":"23","author":"Fay","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib55","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/apt.14124","article-title":"Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors","volume":"46","author":"Ward","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib56","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/apt.12733","article-title":"A\u00a0prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease","volume":"39","author":"Levesque","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib57","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1053\/j.gastro.2009.07.062","article-title":"Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn\u2019s disease","volume":"137","author":"Karmiris","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib58","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-2036.2008.03828.x","article-title":"Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease","volume":"28","author":"West","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib59","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1093\/ibd\/izy132","article-title":"Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic and histologic remission in Crohn\u2019s disease","volume":"24","author":"Papamichael","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib60","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1136\/gutjnl-2014-307883","article-title":"The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease","volume":"64","author":"Vande Casteele","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib61","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cgh.2014.09.031","article-title":"Factors associated with short- and long-term outcomes of therapy for Crohn's disease","volume":"13","author":"Reinisch","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib62","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.dld.2017.11.008","article-title":"Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission inpatients with inflammatory bowel disease","volume":"50","author":"Bodini","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib63","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ajg.2013.12","article-title":"Antibody response to infliximab and its impact on pharmacokinetics can be transient","volume":"108","author":"Vande Casteele","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib64","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/MIB.0000000000000137","article-title":"Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease","volume":"20","author":"Singh","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib65","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/ecco-jcc\/jjw085","article-title":"Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis","volume":"10","author":"Farkas","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib66","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1038\/ctg.2016.62","article-title":"Rapid test for infliximab drug concentration allows immediate dose adaptation","volume":"7","author":"Van Stappen","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib67","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cgh.2015.11.014","article-title":"Infliximab concentration thresholds during induction therapy are associated with short-term mucosal healing in patients with ulcerative colitis","volume":"14","author":"Papamichael","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cgh.2014.07.055","article-title":"A\u00a0panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis","volume":"13","author":"Arias","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib69","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","article-title":"Infliximab trough levels may predict sustained response to infliximab in patients with Crohn\u2019s disease","volume":"7","author":"Bortlik","year":"2013","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00535-013-0807-0","article-title":"C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease","volume":"49","author":"Hibi","year":"2014","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib71","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","article-title":"Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial","volume":"63","author":"Cornillie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib72","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1097\/MIB.0000000000000769","article-title":"Serum infliximab, antidrug antibodies, and tumor necrosis factor predict sustained response in pediatric Crohn's disease","volume":"22","author":"Stein","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib73","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/apt.14410","article-title":"Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy","volume":"47","author":"Bar-Yoseph","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib74","first-page":"549","article-title":"Association of induction infliximab levels with clinical response in perianal Crohn's disease","volume":"11","author":"Davidov","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib75","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/apt.14452","article-title":"Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn\u2019s disease who lose clinical response","volume":"47","author":"Dreesen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2019.03.037_bib76","doi-asserted-by":"crossref","first-page":"S063","DOI":"10.1093\/ecco-jcc\/jjx180.084","article-title":"Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn\u2019s disease: pharmacokinetic\u2013pharmacodynamic analysis of TAILORIX","volume":"12","author":"Dreesen","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib77","first-page":"697","article-title":"Prediction of short- and medium-term efficacy of biosimilar infliximab therapy: do trough levels and antidrug antibody levels or clinical and biochemical markers play the more important role?","volume":"11","author":"Gonczi","year":"2017","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00535-015-1102-z","article-title":"First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis: results from a multicenter prospective randomized controlled trial and its post hoc analysis","volume":"51","author":"Kobayashi","year":"2016","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib79","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/ecco-jcc\/jjw067","article-title":"Long-term outcome of patients with ulcerative colitis and primary non-response to infliximab","volume":"10","author":"Papamichael","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib80","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MCG.0000000000000375","article-title":"Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease","volume":"50","author":"Steenholdt","year":"2016","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib81","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1097\/MIB.0b013e3182a77b41","article-title":"Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study","volume":"19","author":"Paul","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib82","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/ibd\/izy203","article-title":"Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD","volume":"25","author":"Lega","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.dld.2015.10.023","article-title":"Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease","volume":"48","author":"Guiotto","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab\u2019)2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"Ben-Horin","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib85","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/apt.13299","article-title":"Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice","volume":"42","author":"Buurman","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10620-018-4917-7","article-title":"Long-term outcome of infliximab optimization for overcoming immunogenicity in patients with inflammatory bowel disease","volume":"63","author":"Papamichael","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2019.03.037_bib87","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib88","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib89","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.cgh.2017.03.032","article-title":"Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease","volume":"15","author":"Battat","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib90","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cgh.2018.04.040","article-title":"Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases","volume":"16","author":"Dreesen","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib91","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/apt.14548","article-title":"Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease: a multicentre prospective observational study","volume":"47","author":"Yacoub","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib92","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.cgh.2016.11.023","article-title":"Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months","volume":"15","author":"Williet","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib93","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ecco-jcc\/jjv241","article-title":"Variability in golimumab exposure: a \u2018real-life\u2019 observational study in active ulcerative colitis","volume":"10","author":"Detrez","year":"2016","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/apt.14421","article-title":"Exposure\u2013response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn\u2019s disease","volume":"47","author":"Vande Casteele","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib95","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cgh.2013.10.025","article-title":"Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn\u2019s disease","volume":"12","author":"Colombel","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib96","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.gastro.2017.07.032","article-title":"American Gastroenterological Association Institute guideline on therapeutic drug monitoring in inflammatory bowel disease","volume":"153","author":"Feuerstein","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib97","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib98","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ibd\/izy044","article-title":"Therapeutic drug monitoring guides the management of crohn's patients with secondary loss of response to adalimumab","volume":"24","author":"Restellini","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib99","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/gutjnl-2013-305279","article-title":"Individualised therapy is more cost-effective than dose intensification in patients with Crohn\u2019s disease who lose response to anti-TNF treatment: a randomised, controlled trial","volume":"63","author":"Steenholdt","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib100","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1007\/s10620-015-3581-4","article-title":"Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn\u2019s disease patients failing infliximab","volume":"60","author":"Steenholdt","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2019.03.037_bib101","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.cgh.2012.12.035","article-title":"A\u00a0test-based strategy is more cost effective than empiric dose escalation for patients with Crohn\u2019s disease who lose responsiveness to infliximab","volume":"11","author":"Velayos","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib102","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjy076","article-title":"Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study","author":"Guidi","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib103","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","article-title":"Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease","volume":"12","author":"Papamichael","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib104","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clinre.2015.05.019","article-title":"Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission","volume":"40","author":"Amiot","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib106","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/MIB.0000000000001258","article-title":"Infliximab therapeutic drug monitoring changes clinical decisions in a virtual biologics clinic for inflammatory bowel disease","volume":"23","author":"Selinger","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib107","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.dld.2018.08.029","article-title":"Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: a discrete event model study","volume":"51","author":"Attar","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib108","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib109","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.13754","article-title":"Prognostic factors for long-term infliximab treatment in Crohn\u2019s disease patients: a 20-year single centre experience","volume":"44","author":"Billiet","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib110","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ajg.2010.9","article-title":"Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease","volume":"105","author":"Afif","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib111","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ecco-jcc\/jjv004","article-title":"Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn\u2019s disease","volume":"9","author":"Steenholdt","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib112","article-title":"Combination therapy with infliximab and azathioprine improves infliximab pharmacokinetic features and efficacy: a post-hoc analysis","author":"Colombel","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib113","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/ibd\/izy272","article-title":"Vedolizumab drug level correlation with clinical remission, biomarker normalization, and mucosal healing in inflammatory bowel disease","volume":"25","author":"Al-Bawardy","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib114","doi-asserted-by":"crossref","DOI":"10.1097\/FTD.0000000000000565","article-title":"Short communication: evaluation of infliximab and anti-infliximab LISA-TRACKER immunoassays for the therapeutic drug monitoring of SB2 infliximab biosimilar","author":"Jentzer","year":"2018","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cgh.2019.03.037_bib115","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1177\/1756283X17722915","article-title":"Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays","volume":"10","author":"Afonso","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib116","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biologicals.2016.06.011","article-title":"CT-P13 (Inflectra, Remsima) monitoring in patients with inflammatory bowel disease","volume":"44","author":"Schulze","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.cgh.2019.03.037_bib117","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MIB.0000000000000709","article-title":"Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples","volume":"22","author":"Gils","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib118","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/ajg.2014.106","article-title":"Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn\u2019s disease: post hoc analysis of a randomized controlled trial","volume":"109","author":"Steenholdt","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib119","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/gutjnl-2016-313071","article-title":"Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial","volume":"67","author":"Van Stappen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2019.03.037_bib120","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ibd.21919","article-title":"Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies","volume":"18","author":"Kopylov","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/apt.12030","article-title":"Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays","volume":"36","author":"Vande Casteele","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib122","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1136\/flgastro-2016-100692","article-title":"Assays for measurement of TNF antagonists in practice","volume":"8","author":"Vande Casteele","year":"2017","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib123","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1208\/s12248-016-9981-3","article-title":"comparisons of serum infliximab and antibodies-to-infliximab tests used in inflammatory bowel disease clinical trials of Remicade","volume":"19","author":"Marini","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.cgh.2019.03.037_bib124","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib125","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib126","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ajg.2017.21","article-title":"Therapeutic drug monitoring in IBD: the new standard-of-care for anti-TNF Therapy","volume":"112","author":"Papamichael","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2019.03.037_bib127","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1053\/j.gastro.2018.01.001","article-title":"Using proactive therapeutic drug monitoring of anti-tumor necrosis factor therapy in inflammatory bowel disease: from an old concept to a future standard of care?","volume":"154","author":"Papamichael","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2019.03.037_bib128","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz018","article-title":"Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease","author":"Papamichael","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib129","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz008","article-title":"Ustekinumab exposure-outcome analysis in Cohn's disease only in part explains limited endoscopic remission rates","author":"Verstockt","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib130","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjz029","article-title":"Vedolizumab trough levels and histological healing during maintenance therapy in ulcerative colitis","author":"Pouillon","year":"2019","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2019.03.037_bib131","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/apt.15113","article-title":"Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation","volume":"49","author":"Osterman","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib132","article-title":"Infliximab exposure-response relationship and thresholds associated with endoscopic healing in patients with ulcerative colitis","author":"Vande Casteele","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2019.03.037_bib133","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/apt.15046","article-title":"Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring","volume":"49","author":"Lucidarme","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2019.03.037_bib134","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/ibd\/izx023","article-title":"A\u00a0survey study of gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease","volume":"24","author":"Grossberg","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2019.03.037_bib135","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1208\/s12248-018-0237-2","article-title":"Dashboards for therapeutic monoclonal antibodies: learning and confirming","volume":"20","author":"Mould","year":"2018","journal-title":"AAPS J"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519303015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356519303015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:29:40Z","timestamp":1761542980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356519303015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":135,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1542356519303015"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735431918.793568132","asserted-by":"object"}]},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}